Autonomic Nervous System Drugs Practice Questions

Q: Prolonged apnea may occur in patients with a genetically determined abnormal variant of cholinesterase following intravenous administration of which of the following drugs?

Succinylcholine. **Explanation:** The correct answer is **Succinylcholine**. **Mechanism and Pathophysiology:** Succinylcholine is a depolarizing neuromuscular blocker that is rapidly hydrolyzed by **pseudocholinesterase** (also known as plasma cholinesterase or butyrylcholinesterase). In normal individuals, its duration of action is very short (5–10 minutes). However, patients with a genetically determined **atypical pseudocholinesterase** (autosomal recessive condition) cannot metabolize the drug efficiently. This leads to a prolonged neuromuscular block, resulting in **scoline apnea**, where the patient remains paralyzed and unable to breathe spontaneously for hours after a standard dose. **Analysis of Incorrect Options:** * **Pancuronium & Tubocurarine:** These are long-acting, non-depolarizing neuromuscular blockers. They are primarily eliminated by the kidneys and liver, not by plasma cholinesterase. * **Atracurium:** This is an intermediate-acting non-depolarizing agent. It is unique because it undergoes **Hofmann elimination** (spontaneous degradation at body temperature and pH) and ester hydrolysis. It does not rely on pseudocholinesterase and is safe in patients with this genetic variant. **NEET-PG High-Yield Pearls:** * **Screening Test:** The quality of the enzyme is measured by the **Dibucaine Number**. A normal number is 80; a person with atypical enzyme (homozygous) will have a low number (around 20). * **Management:** The primary treatment for scoline apnea is **continued mechanical ventilation** and sedation until the block wears off spontaneously. * **Fresh Frozen Plasma (FFP):** Can be used to provide exogenous pseudocholinesterase, but is generally avoided due to infection risks. * **Mivacurium:** This is the only non-depolarizing blocker also metabolized by pseudocholinesterase; it would also cause prolonged apnea in these patients.

Q: Which one of the following is a relatively selective 02 adrenergic blocker with a short duration of action?

Yohimbine. **Explanation:** The question asks for a selective **$\alpha_2$ adrenergic blocker** with a short duration of action. **Why Yohimbine is Correct:** Yohimbine is an alkaloid derived from the bark of the *Pausinystalia johimbe* tree. It acts as a **competitive, selective $\alpha_2$ receptor antagonist**. By blocking presynaptic $\alpha_2$ receptors, it increases the release of norepinephrine into the synaptic cleft, leading to increased sympathetic outflow. It has a relatively **short half-life (approx. 30–40 minutes)**, necessitating frequent dosing if used clinically. While historically used for erectile dysfunction, its clinical utility is now limited due to side effects like tachycardia and hypertension. **Why the Other Options are Incorrect:** * **Prazosin:** This is a highly selective **$\alpha_1$ blocker**. It is used in the treatment of hypertension and Benign Prostatic Hyperplasia (BPH). It is famous for the "first-dose phenomenon" (postural hypotension). * **Terazosin & Doxazosin:** These are also selective **$\alpha_1$ blockers** similar to Prazosin but have a much **longer duration of action** (Doxazosin has a half-life of ~22 hours), allowing for once-daily dosing. They are primarily used for BPH. **High-Yield NEET-PG Pearls:** * **$\alpha_2$ Agonists vs. Antagonists:** Remember that $\alpha_2$ agonists (Clonidine, Methyldopa) *decrease* sympathetic outflow, while $\alpha_2$ antagonists (Yohimbine, Idazoxan) *increase* it. * **Mirtazapine:** Another clinically important drug with $\alpha_2$ blocking properties, used as an atypical antidepressant. * **Reversal of Toxicity:** Yohimbine can theoretically be used to reverse the toxicity of $\alpha_2$ agonists like Xylazine (common in veterinary medicine). * **Selectivity Rule:** Drugs ending in **"-zosin"** are generally selective $\alpha_1$ blockers.

Q: Which antihistaminic agent possesses a high anticholinergic profile?

Diphenhydramine. **Explanation:** The correct answer is **Diphenhydramine**. **1. Why Diphenhydramine is correct:** Antihistamines are classified into first and second generations. **Diphenhydramine** is a **first-generation H1-receptor antagonist**. These agents are highly lipophilic (crossing the blood-brain barrier) and lack selectivity for the H1 receptor. They significantly antagonize **muscarinic receptors**, leading to a high anticholinergic profile. This results in classic side effects such as dry mouth, blurred vision, urinary retention, and constipation. **2. Why the other options are incorrect:** * **Astemizole & Terfenadine (Options A & C):** These are second-generation antihistamines. They were designed to be more selective for peripheral H1 receptors and have minimal to no anticholinergic activity. *Note: Both have been largely withdrawn from the market due to the risk of QT prolongation and Torsades de Pointes.* * **Fexofenadine (Option D):** This is a third-generation (or advanced second-generation) antihistamine and is the active metabolite of terfenadine. It is highly selective for peripheral H1 receptors, does not cross the blood-brain barrier, and is virtually devoid of anticholinergic effects. **3. NEET-PG High-Yield Pearls:** * **First-generation H1 blockers** (e.g., Diphenhydramine, Promethazine, Hydroxyzine) are used clinically for their sedative and anticholinergic properties (e.g., in motion sickness or Parkinsonism). * **Anticholinergic Toxidrome mnemonic:** "Blind as a bat, mad as a hatter, red as a beet, hot as a hare, dry as a bone." * **Fexofenadine** is the "least sedating" antihistamine because it is a substrate for the P-glycoprotein efflux pump in the blood-brain barrier. * **Drug Interaction:** Terfenadine and Astemizole toxicity increases when co-administered with CYP3A4 inhibitors (e.g., Ketoconazole, Erythromycin).

Q: Pseudocholinesterase is synthesized by which organ?

Liver. ### Explanation **Correct Answer: A. Liver** **Underlying Medical Concept:** Cholinesterases are enzymes that hydrolyze acetylcholine. There are two main types: **True Cholinesterase** (Acetylcholinesterase) and **Pseudocholinesterase** (Butyrylcholinesterase or Plasma cholinesterase). While True Cholinesterase is found at neural sites, Pseudocholinesterase is a glycoprotein **synthesized primarily in the liver** and secreted into the plasma. It has no known physiological function at the synapse but plays a critical role in metabolizing exogenous drugs like Succinylcholine, Mivacurium, and Procaine. **Analysis of Incorrect Options:** * **B. Plasma:** This is the primary *location* where the enzyme functions, but it is not the site of *synthesis*. Confusing the site of action with the site of production is a common examiner trap. * **C. Muscle end plate:** This is the site for **True Cholinesterase**. It is required here for the rapid termination of signal transmission by breaking down acetylcholine released from motor neurons. * **D. Nerve ending:** Similar to the muscle end plate, cholinergic nerve endings (synaptic clefts) contain True Cholinesterase to ensure discrete, non-repetitive nerve impulses. **Clinical Pearls for NEET-PG:** 1. **Succinylcholine Apnea:** Patients with a genetic deficiency of Pseudocholinesterase or liver disease (reduced synthesis) cannot metabolize Succinylcholine efficiently, leading to prolonged muscle paralysis and respiratory failure. 2. **Dibucaine Number:** This test is used to identify atypical Pseudocholinesterase. A low Dibucaine number indicates an abnormal enzyme that cannot hydrolyze Succinylcholine. 3. **Organophosphate Poisoning:** Both enzymes are inhibited. However, Pseudocholinesterase levels (Plasma levels) fall faster than RBC cholinesterase, making it a sensitive early marker for exposure.

Q: Botulinum toxin is used for the treatment of which of the following conditions?

All of the above. **Explanation:** Botulinum toxin, produced by the bacterium *Clostridium botulinum*, is a potent neurotoxin that acts by inhibiting the release of **Acetylcholine (ACh)** from the presynaptic nerve terminals at the neuromuscular junction. This results in flaccid paralysis of the affected muscles, a property utilized therapeutically to treat conditions characterized by muscle overactivity or spasms. * **Blepharospasm (Option A):** This is an abnormal contraction or twitching of the eyelids. Botulinum toxin (Botox) is the first-line treatment, injected locally to relax the orbicularis oculi muscle. * **Risus Sardonicus (Option B):** This is a highly characteristic "sardonic grin" caused by spasms of the facial muscles, typically seen in **Tetanus** or **Strychnine poisoning**. While it is a clinical sign rather than a primary disease, Botulinum toxin can be used to alleviate the underlying focal muscle spasticity. * **Strabismus (Option C):** Also known as "crossed eyes," it involves a misalignment of the eyes. Injecting the toxin into the overactive extraocular muscle allows the opposing muscle to tighten, thereby realigning the eyes. **Clinical Pearls for NEET-PG:** * **Mechanism:** Proteolysis of **SNARE proteins** (Synaptobrevin, SNAP-25, and Syntaxin), preventing vesicle fusion. * **Fatal Dose:** It is the most poisonous substance known; the lethal dose is approximately 1–3 ng/kg. * **Other Uses:** Achalasia cardia, Hyperhidrosis (excessive sweating), Migraine prophylaxis, and cosmetic reduction of wrinkles. * **Infant Botulism:** Associated with the ingestion of **honey** containing spores (Floppy Baby Syndrome).

Q: Which of the following physiological activities is NOT mediated through β2 adrenergic receptors?

Stimulation of lipolysis. **Explanation:** The correct answer is **A. Stimulation of lipolysis**. **1. Why Option A is correct:** Lipolysis (the breakdown of lipids into fatty acids) is primarily mediated by **$\beta_3$ adrenergic receptors** (and to a lesser extent $\beta_1$ receptors) located in adipose tissue. While $\beta_2$ receptors are widely distributed, they do not play a significant role in the stimulation of lipolysis. **2. Why the other options are incorrect:** * **B & C (Metabolic effects):** $\beta_2$ receptors are the primary mediators of catecholamine-induced hyperglycemia. They stimulate **hepatic gluconeogenesis** and **glycogenolysis** (Option B) as well as **muscle glycogenolysis** (Option C). This provides immediate energy substrates during a "fight or flight" response. * **D (Smooth muscle relaxation):** The hallmark of $\beta_2$ receptor activation is the relaxation of smooth muscles. This includes **bronchodilation** (lungs), **vasodilation** (skeletal muscle blood vessels), and **uterine relaxation** (tocolysis). **High-Yield NEET-PG Pearls:** * **$\beta_1$ Location:** Primarily Heart (Inotropy/Chronotropy) and Juxtaglomerular cells (Renin release). Remember: *"1 Heart."* * **$\beta_2$ Location:** Lungs, Blood vessels, GI tract, Bladder, Uterus, and Liver. Remember: *"2 Lungs."* * **$\beta_3$ Location:** Adipose tissue (Lipolysis) and Detrusor muscle (Mirabegron is a $\beta_3$ agonist used for overactive bladder). * **Potassium Shift:** $\beta_2$ stimulation promotes the uptake of potassium into skeletal muscles (via Na+/K+ ATPase), which can lead to **hypokalemia**. This is why Salbutamol is used in the emergency management of hyperkalemia.

Q: Dry skin seen due to excess dosage of datura is due to which of the following mechanisms?

Absence of sweating. The correct answer is **B. Absence of sweating**. Datura contains belladonna alkaloids, primarily **Atropine** and **Scopolamine**, which act as competitive antagonists at **Muscarinic (M) receptors** [3, 4]. 1. **Mechanism:** Sweat glands are innervated by sympathetic cholinergic fibers. These fibers release acetylcholine, which acts on **M3 receptors** to stimulate sweating. Datura alkaloids block these M3 receptors, leading to a complete suppression of sweat production (**Anhidrosis**). Since evaporation of sweat is the primary mechanism for heat loss, the skin becomes characteristically **dry and hot** [1, 2]. 2. **Why other options are wrong:** * **Vasodilatation (A):** While atropine poisoning causes "Atropine Flush" (cutaneous vasodilation), this makes the skin *red*, not dry. The dryness is specifically a secretory failure. * **Central action (C):** While Datura causes CNS effects (delirium, hallucinations), the dry skin is a peripheral effect on the effector organ (sweat glands). * **Change in BMR (D):** Datura does not significantly alter the basal metabolic rate; the rise in body temperature is due to the inability to dissipate heat (hyperpyrexia), not increased heat production [1]. **NEET-PG High-Yield Pearls:** * **The Mnemonic for Atropine/Datura Poisoning:** * *Dry as a bone* (Anhidrosis/Dry skin) [2] * *Red as a beet* (Cutaneous vasodilation) * *Blind as a bat* (Mydriasis/Cycloplegia) [2] * *Hot as a hare* (Hyperpyrexia) [1] * *Mad as a hatter* (Delirium/Psychosis) * **Antidote of choice:** **Physostigmine** (a tertiary amine carbamate that crosses the Blood-Brain Barrier). * **Clinical Sign:** "Dry skin" is a crucial differentiating feature between Datura poisoning and OP poisoning (where skin is moist/diaphoretic).

Q: Which of the following is NOT an action of epinephrine when administered intravenously in a high dose?

Causes bronchiolar constriction. **Explanation:** Epinephrine (Adrenaline) is a potent agonist at both **alpha (α₁, α₂)** and **beta (β₁, β₂, β₃)** adrenergic receptors. The question asks for the action that is NOT produced by epinephrine. **1. Why Option B is correct:** Epinephrine acts on **β₂ receptors** located in the bronchial smooth muscle. Activation of these receptors leads to **bronchodilation**, not constriction. This is why epinephrine is a life-saving drug in acute bronchial asthma and anaphylaxis. Bronchoconstriction is typically mediated by the parasympathetic system (M₃ receptors) or inflammatory mediators like histamine and leukotrienes. **2. Why the other options are incorrect:** * **Option A (Liver glycogenolysis):** Epinephrine stimulates **β₂ and α₁ receptors** in the liver, promoting the breakdown of glycogen into glucose. This increases blood glucose levels to provide energy during "fight or flight" situations. * **Option C (Extrasystoles):** Through **β₁ receptors** in the myocardium, epinephrine increases heart rate (chronotropy) and excitability. High doses can trigger ectopic foci, leading to extrasystoles or arrhythmias. * **Option D (Restlessness and anxiety):** Although epinephrine crosses the blood-brain barrier poorly, high IV doses cause significant peripheral physiological changes (palpitations, tremors) and some central stimulation, manifesting as anxiety, restlessness, and apprehension. **High-Yield NEET-PG Pearls:** * **Drug of Choice (DOC):** Epinephrine (1:1000 IM) is the DOC for **Anaphylactic Shock**. * **Vasomotor Reversal of Dale:** If an α-blocker (e.g., phentolamine) is given before epinephrine, the α-mediated vasoconstriction is blocked, leaving only β₂-mediated vasodilation, causing a fall in BP instead of a rise. * **Metabolism:** Epinephrine is metabolized by **MAO** and **COMT**; the end product excreted in urine is **Vanillylmandellic acid (VMA)**.

Q: Which statement is true regarding dobutamine?

Dobutamine decreases peripheral resistance.. **Explanation:** Dobutamine is a synthetic catecholamine primarily used as a positive inotropic agent. Its pharmacological profile is unique due to its action on multiple adrenergic receptors. **1. Why Option A is correct:** Dobutamine is a relatively selective **$\beta_1$-agonist**, but it also possesses activity at $\beta_2$ and $\alpha_1$ receptors. While its $\beta_1$ effect increases cardiac output, its **$\beta_2$-agonist activity** leads to vasodilation in the skeletal muscle vascular bed. This results in a **decrease in total peripheral resistance (TPR)**. Although it has some $\alpha_1$ agonist activity (which causes vasoconstriction), the $\beta_2$ effect usually predominates or balances it out, leading to a net reduction in afterload. **2. Why the other options are incorrect:** * **Option B:** Unlike dopamine, dobutamine **does not act on Dopaminergic (D1 or D2) receptors**. It is purely an adrenergic agonist. * **Option C:** Dobutamine generally **increases renal blood flow**. This is not due to direct D1 stimulation (like dopamine), but rather a secondary effect of increased cardiac output and improved systemic hemodynamics. * **Option D:** Dobutamine **increases coronary blood flow** due to increased cardiac work and secondary metabolic vasodilation, as well as direct $\beta_2$ effects on coronary vessels. **Clinical Pearls for NEET-PG:** * **Drug of Choice:** Dobutamine is the preferred inotrope for **Cardiogenic Shock** (without severe hypotension) and **Acute Decompensated Heart Failure**. * **Dobutamine Stress Echo:** Used to diagnose ischemic heart disease in patients unable to exercise; it increases myocardial oxygen demand to reveal wall motion abnormalities. * **Isomeric property:** The (+)-isomer is a powerful $\beta$ agonist, while the (-)-isomer is an $\alpha_1$ agonist. In clinical racemic mixtures, the $\beta$ effects predominate.

Question 1

Prolonged apnea may occur in patients with a genetically determined abnormal variant of cholinesterase following intravenous administration of which of the following drugs?

Accepted Answer

Succinylcholine

Answer

Pancuronium

Answer

Tubocurarine

Answer

Atracurium

Question 2

Which of the following drugs should be avoided in a patient with adrenaline-producing pheochromocytoma?

Accepted Answer

Phentolamine

Answer

Enalapril

Answer

Clonidine

Answer

Methyldopa

Question 3

Which one of the following is a relatively selective 02 adrenergic blocker with a short duration of action?

Accepted Answer

Yohimbine

Answer

Prazosin

Answer

Terazosin

Answer

Doxazosin

Question 4

Which antihistaminic agent possesses a high anticholinergic profile?

Accepted Answer

Diphenhydramine

Answer

Astemizole

Answer

Terfenadine

Answer

Fexofenadine

Question 5

Pseudocholinesterase is synthesized by which organ?

Accepted Answer

Liver

Answer

Plasma

Answer

Muscle end plate

Answer

Nerve ending

Question 6

Botulinum toxin is used for the treatment of which of the following conditions?

Accepted Answer

All of the above

Answer

Blepharospasm

Answer

Risus sardonicus

Answer

Strabismus

Question 7

Which of the following physiological activities is NOT mediated through β2 adrenergic receptors?

Accepted Answer

Stimulation of lipolysis

Answer

Increased hepatic gluconeogenesis

Answer

Increased muscle glycogenolysis

Answer

Smooth muscle relaxation

Question 8

Dry skin seen due to excess dosage of datura is due to which of the following mechanisms?

Accepted Answer

Absence of sweating

Answer

Vasodilatation

Answer

Central action

Answer

Change in basal metabolic rate

Question 9

Which of the following is NOT an action of epinephrine when administered intravenously in a high dose?

Accepted Answer

Causes bronchiolar constriction

Answer

Increases liver glycogenolysis

Answer

Evokes extrasystoles in the heart

Answer

Produces restlessness and anxiety

Question 10

Which statement is true regarding dobutamine?

Accepted Answer

Dobutamine decreases peripheral resistance.

Answer

Dobutamine acts on D1 and D2 receptors.

Answer

Dobutamine decreases kidney circulation.

Answer

Dobutamine has no effect on coronary circulation.

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?